# Black Sesame Pigment Ameliorates Non-Alcoholic Fatty Liver Disease via Modulation of the Gut–Liver Axis and HIF-1 Signaling Pathway

**Authors:** Qian Huang, Zhuowen Liang, Qingpeng Li, Ke Wang, Shuang Zhu, Wei Xiao, Lin Zhou

PMC · DOI: 10.3390/antiox15020177 · Antioxidants · 2026-01-30

## TL;DR

Black sesame pigment improves non-alcoholic fatty liver disease in mice and human liver organoids by altering gut bacteria and liver signaling pathways.

## Contribution

FBSP is shown to ameliorate NAFLD via gut microbiota remodeling and modulation of the HIF-1 signaling pathway in both mouse and human models.

## Key findings

- FBSP treatment reduced hepatic steatosis and dysfunction in NAFLD mice.
- FBSP increased Lactobacillus and Bacteroides in gut microbiota and influenced host metabolism.
- FBSP modulated HIF-1 pathway genes and reduced lipid accumulation in human liver organoids.

## Abstract

Black sesame pigment (BSP), a key macromolecular component of the traditional food–medicine black sesame, holds potential for improving non-alcoholic fatty liver disease (NAFLD), but its mechanisms remain unclear. We evaluated BSP and fired black sesame pigment (FBSP) in a high-fat diet/streptozotocin-induced NAFLD mouse model. An integrated multi-omics strategy—encompassing network pharmacology, urinary metabolomics, and 16S rRNA sequencing—was employed to identify potential targets and pathways. Key findings were subsequently validated in a human liver organoid model of NAFLD. FBSP treatment significantly alleviated hepatic steatosis and dysfunction in mice. Multi-omics analysis revealed that FBSP reshaped the gut microbiota (increasing Lactobacillus and Bacteroides) and influenced host glycolysis/gluconeogenesis metabolism. Both omics predictions converged on the HIF-1 signaling pathway. In human liver organoids, FBSP reduced lipid accumulation and inflammation, and modulated the expression of core HIF-1 pathway genes. This study demonstrates that FBSP ameliorates NAFLD, potentially through a gut–liver axis mechanism that involves microbiota remodeling and subsequent modulation of the hepatic HIF-1 signaling pathway. Our findings position FBSP as a promising food-derived candidate for NAFLD intervention.

## Linked entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091]
- **Diseases:** non-alcoholic fatty liver disease (MONDO:0013209), NAFLD (MONDO:0013209)
- **Species:** Lactobacillus (taxon 1578), Bacteroides (taxon 816)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, alpha-amylase [NCBI Gene 105166249], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Hadh (hydroxyacyl-Coenzyme A dehydrogenase) [NCBI Gene 15107] {aka HCDH, Hadhsc, Schad}, Egf (epidermal growth factor) [NCBI Gene 13645], Mapk3 (mitogen-activated protein kinase 3) [NCBI Gene 26417] {aka Erk-1, Erk1, Ert2, Esrk1, Mnk1, Mtap2k}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, Lpin1 (lipin 1) [NCBI Gene 14245] {aka Lipin1, fld}, Hgf (hepatocyte growth factor) [NCBI Gene 15234] {aka C230052L06Rik, HGF/SF, NK1, NK2, SF, SF/HGF}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Cpt2 (carnitine palmitoyltransferase 2) [NCBI Gene 12896] {aka CPTII}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Bsp (black spleen) [NCBI Gene 103993], Fgf10 (fibroblast growth factor 10) [NCBI Gene 14165] {aka AEY17, Fgf-10, Fgf5a, Gsfaey17}, Alb (albumin) [NCBI Gene 11657] {aka Alb-1, Alb1, BCL001, BCL002, BPL001}, Apoc2 (apolipoprotein C2) [NCBI Gene 11813] {aka apo-CII, apoC-II}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Gast (gastrin) [NCBI Gene 14459] {aka GAS}, Afp (alpha fetoprotein) [NCBI Gene 11576], Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}
- **Diseases:** metabolic syndrome (MESH:D024821), cirrhosis (MESH:D005355), liver abnormalities (MESH:D008107), Inflammation (MESH:D007249), injury to (MESH:D014947), mitochondrial dysfunction (MESH:D028361), diabetes (MESH:D003920), NAFL (MESH:D065626), glucose metabolism disorders (MESH:D044882), edema (MESH:D004487), NASH (MESH:D005235), obesity (MESH:D009765), hypoxic (MESH:D002534), hepatic steatosis (MESH:D005234), metabolic diseases (MESH:D008659), hepatic ischemia (MESH:D007511), Hypoxia (MESH:D000860), reperfusion injury (MESH:D015427), DC (MESH:D054221), hepatic insulin resistance (MESH:D007333), alcoholic liver disease (MESH:D008108), type 2 diabetes (MESH:D003924), liver (MESH:D017093), hepatic (MESH:D056486), necrosis (MESH:D009336), hepatic lipid (MESH:D011017), intestinal and liver disease (MESH:D007410), HCC (MESH:D006528)
- **Chemicals:** gold (MESH:D006046), Paraffin (MESH:D010232), platinum (MESH:D010984), fat (MESH:D005223), pyruvate (MESH:D019289), oxygen (MESH:D010100), guanidinosuccinic acid (MESH:C001318), K2HPO4 (MESH:C013216), N2 (MESH:D009584), polysaccharides (MESH:D011134), lactate (MESH:D019344), tricarboxylic acid (MESH:D014233), streptomycin (MESH:D013307), Triton X-100 (MESH:D017830), TG (MESH:D014280), metformin (MESH:D008687), nicotinamide (MESH:D009536), water (MESH:D014867), Oil Red O (MESH:C011049), chrysophanol (MESH:C027113), STZ (MESH:D013311), TRIzol (MESH:C411644), catechin (MESH:D002392), glycogen (MESH:D006003), FFAs (MESH:D005230), indoles (MESH:D007211), HCl (MESH:D006851), copper (MESH:D003300), gondoic acid (MESH:C572289), calcium chloride (MESH:D002122), D-biotin (MESH:D001710), Ceramide (MESH:D002518), Blood Glucose (MESH:D001786), NaOH (MESH:D012972), cholesterol (MESH:D002784), phytosphingosine (MESH:C012491), Y-27632 (MESH:C108830), H&amp;E (MESH:D006371), BAs (MESH:D001647), aluminum (MESH:D000535), Alexa Fluor (-), NaHCO3 (MESH:D017693), Hepes (MESH:D006531), Hematoxylin (MESH:D006416), penicillin (MESH:D010406), sodium citrate (MESH:D000077559), forskolin (MESH:D005576), lignans (MESH:D017705), oxaloacetate (MESH:D062907), oil (MESH:D009821), L-arginine (MESH:D001120), fatty acid (MESH:D005227), carbohydrates (MESH:D002241), PC (MESH:C053518), glutamine (MESH:D005973), aminomalonic acid (MESH:C019249), melanin (MESH:D008543), pedalitin (MESH:C510777), 2-naphthylamine (MESH:D015081), Lipid (MESH:D008055)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Lactobacillus (genus) [taxon 1578], Allobaculum (genus) [taxon 174708], Bacteroides (genus) [taxon 816], Homo sapiens (human, species) [taxon 9606], Bifidobacterium (genus) [taxon 1678], Akkermansia (genus) [taxon 239934], Bacteroidales (order) [taxon 171549], Sesamum indicum (beniseed, species) [taxon 4182]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938165/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938165/full.md

## References

77 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938165/full.md

---
Source: https://tomesphere.com/paper/PMC12938165